ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Baclofen Effects on Smoking Urge and Withdrawal

This study is currently recruiting participants.
Verified by Department of Veterans Affairs, July 2008

Sponsored by: Department of Veterans Affairs
Information provided by: Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT00257894
  Purpose

The purpose of this study is to determine whether baclofen is effective in reducing smoking urge, withdrawal, and reinforcement in moderate to heavy cigarette smokers.


Condition Intervention
Nicotine Use Disorder
Nicotine Dependence
Smoking
Tobacco Use Disorder
Drug: Baclofen

MedlinePlus related topics:   Smoking   

ChemIDplus related topics:   Baclofen    Nicotine polacrilex    Nicotine tartrate   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double Blind (Subject, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study
Official Title:   Baclofen Effects on Smoking Urge and Withdrawal

Further study details as provided by Department of Veterans Affairs:

Primary Outcome Measures:
  • Three measures are equally important: 1) Total score on Questionnaire of Smoking Urges; 2) Minnesota Nicotine Withdrawal Scale, 3) Number of choices for cigarette puffs vs. financial incentive in a behavioral economics procedure. [ Time Frame: Measures are assessed on the tenth day of medication titration, after 5 hours of smoking deprivation. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Nicotine self-administration as quantified by salivary cotinine boost during a behavioral self-administration task. [ Time Frame: Measures are assessed on the tenth day of medication titration, after 5 hours of smoking deprivation. ] [ Designated as safety issue: No ]

Estimated Enrollment:   64
Study Start Date:   December 2005
Estimated Study Completion Date:   December 2008
Estimated Primary Completion Date:   December 2008 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
1: Placebo Comparator
Healthy people from the surrounding community who smoke at least 10 cigarettes per day and not ready to quit smoking
Drug: Baclofen
Dosing taken orally for a total of 12 days: 40mg/day vs. 20mg/day vs. 0mg/day (placebo tabs). The 40mg condition will receive 15mg/day the first 3 days(Days 1,2,3), 30mg/day for 3 days(Days 4,5,6), and 40mg/day for 3 days(Days 7,8,9). The 20mg/day condition will receive 15mg/day the first 3 days(Days 1,2,3) and 20mg/day for the next 6 days(Days4-9). Downward titration: 40mg/day condition will receive 40mg/day(Day 10), 20mg/day(Day 11), and 10mg/day(Day 12). 20mg/day condition will receive 20mg/day(Day10), 10mg/day(Day11), and 5mg/day(Day12).

Detailed Description:

OBJECTIVES: The long-term objective of this research program is to improve treatments for tobacco smokers by investigating the effects of medications on self-reported and psychophysiological responses to smoking cues and on behavioral-economic measures of smoking reinforcement during a period of tobacco deprivation. The specific objectives of the present application are to investigate the dose-response effects of baclofen (a GABA-B agonist), 1) on urge, and withdrawal, and 2) on the reinforcement value of smoking as measured by choices for puffs on cigarettes versus an alternative reinforcer among current smokers after 4 hours of smoking deprivation.

RESEARCH PLAN: The study will use a randomized placebo-controlled between-subjects design with 64 smokers to investigate the effects of placebo and two doses (20 or 40 mg/day) of baclofen on urge to smoke and withdrawal and on choices for smoking versus money after 4 hours of deprivation.

METHODS: Participants will be healthy people who smoke at least 10 cigarettes per day and who are motivated for future smoking cessation. On Day 0, a baseline session will occur after 4 hours of smoking deprivation and on Day 10 of medication the same assessments will be repeated after the final medication dose has been stabilized for at least 3 days and after 4 hours of supervised smoking deprivation has occurred. Medication differences in urge and withdrawal and in the reinforcement value of smoking cigarettes will be investigated. Dependent measures of urge and withdrawal will be by self-report. The dependent measure of reinforcement value is the ratio of choices for cigarette puffs versus money during a subsequent 2-1/2 hr period. The choice procedure will clarify the relative reinforcement value of smoking while controlling for non-specific decreases in general activity level resulting from sedation. Nicotine self-administration during the medication period will be quantified using saliva cotinine, as a secondary effect.

CLINICAL RELEVANCE: More effective interventions for tobacco use could result in less suffering and mortality and in considerable savings in health care costs associated with cardiovascular disease, pulmonary disorders, and cancer.

  Eligibility
Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Smoke at least 10 cigarettes per day for at least 6 months and considering quitting smoking in the next 6 months-

Exclusion Criteria:

  • Planning to attempt smoking cessation within the next 4 months
  • Weight less than 110 lbs. or above 220 lbs.
  • Use of tobacco products other than cigarettes in the previous month.
  • History of: Kidney disease, uncontrolled conditions (e.g., cardiac disease, pulmonary disease, diabetes, hypertension) Neurological disease (including stroke, mini-stroke, brain injury, Alzheimers Disease, encephalitis, meningitis, seizure disorder),Phenylketonuria Schizophrenia, Schizoaffective Disorder, Paranoid Disorder, or Schizotypal Disorder.
  • Current alcohol and/or drug use disorder as indicated by a screening questionnaire, past treatment for alcohol or substance use problems unless in remission(clean and sober for past year or more) or intention to seek treatment in the next 6 months for alcohol or substance use problems.
  • For women: Pregnancy, nursing, not using a reliable form of birth control.
  • Allergy to baclofen, Lioresal, or Kemstro.
  • Taking the following medications: antidepressants(excluding SSRIs), bupropion, phenothiazines, antihistamines, sedative/hypnotics, benzodiazepines, alpha blockers, beta blockers.
  • Lives with someone enrolled in the study.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00257894

Contacts
Contact: Rebecca R Swagger, MA     (401) 273-7100 ext 3872     rebecca.swagger@va.gov    

Locations
United States, Rhode Island
VA Medical Center, Providence     Recruiting
      Providence, Rhode Island, United States, 02908
      Contact: Regina Correa-Murphy     401-273-7100 ext 3478     regina.correa-Murphy@va.gov    
      Contact: Robert M Swift, MD PhD AB     (401) 457-3066     Robert.Swift@va.gov    
      Principal Investigator: Damaris Rohsenow, PhD            

Sponsors and Collaborators

Investigators
Principal Investigator:     Damaris Rohsenow, PhD     VA Medical Center, Providence    
  More Information


Publications of Results:

Responsible Party:   Department of Veterans Affairs ( Rohsenow, Damaris - Principal Investigator )
Study ID Numbers:   NEUA-029-04F
First Received:   November 21, 2005
Last Updated:   July 31, 2008
ClinicalTrials.gov Identifier:   NCT00257894
Health Authority:   United States: Federal Government

Keywords provided by Department of Veterans Affairs:
Baclofen  
Conditioning, Classical  
Nicotine  
Smoking  

Study placed in the following topic categories:
Nicotine polacrilex
Smoking
Nicotine
Mental Disorders
Tobacco Use Disorder
Baclofen
Substance-Related Disorders
Disorders of Environmental Origin

Additional relevant MeSH terms:
Neurotransmitter Agents
Disease
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Neuromuscular Agents
Pharmacologic Actions
Habits
Pathologic Processes
Muscle Relaxants, Central
Therapeutic Uses
GABA Agonists
GABA Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on September 19, 2008




Links to all studies - primarily for crawlers